

Miracor announces PiCSO Therapy clinical data to be presented at EuroPCR 2018

Awans Belgium, May 17th 2018

Miracor Medical SA (www.miracormedical.com) today announced that new clinical data of the PiCSO® Impulse System for the treatment of STEMI patients will be presented during the EuroPCR conference in Paris, May 21st - 24th 2018.

The PiCSO clinical results will be presented during two different sessions, including a Hotline session:

Thursday May 24th @ 11:03 in the "Hotline Coronary Intervention" session, Room Maillot ***"OXAMI-PiCSO: index of microcirculatory resistance-guided therapy with pressure control intermittent coronary sinus occlusion improves coronary microvascular function and reduces infarct size in STEMI"*** presented by Dr. Gianluigi De Maria, MD, the Heart Centre, Oxford University Hospitals, Oxford, UK.

Thursday May 24th @ 10:40 during the session: "How to reduce Infarct Size and to improve outcomes in STEMI: an insight on novel strategies", Posters Lab. ***"Pressure-controlled intermittent coronary sinus occlusion reduces infarct size after primary PCI: a propensity-controlled matched study"*** presented by Dr Mohamed Egred, MD, Newcastle-On-Tyne, UK.

About Miracor Medical

Miracor Medical (www.miracormedical.com), located in Awans, Belgium, provides innovative solutions for the treatment of severe cardiac diseases, aiming to improve short- and long-term clinical outcomes and reduce associated costs.

Miracor Medical develops the PiCSO Impulse System, the first and only coronary sinus intervention designed to reduce infarct size, improve cardiac function and potentially reduce the onset of heart failure following acute myocardial infarction.

In early January 2018, Miracor Medical announced a financing round of 25M€, and has relocated from Vienna, Austria to Awans, Belgium.

#####

NOTE: The PiCSO® Impulse System is not commercially available.

Contact:

Olivier Delporte

CEO

Miracor Medical SA

odelporte@miracormedical.com